OrganOx Secures Second Private Placement with Intuitive and Terumo Ventures Investments

OrganOx Ltd., a leading company in organ medical technology, has successfully concluded the second closing of its private placement, securing investments from Intuitive Ventures, Terumo Ventures, and Piper Heartland Healthcare LLC. This round of investment, combined with the initial closing in February 2025, has allowed OrganOx to amass a total of $160 million in equity financing. The funds will be used to enhance growth opportunities for its metra® platform technology in the expanding global organ technology market.

The metra® platform, a normothermic machine perfusion (NMP) technology, is approved across the United States, Europe, Canada, and Australia. It has been employed in over 5,000 liver transplants so far. The technology maintains donor livers in a metabolically active state outside the human body, which permits transplant teams to conduct functional assessments before transplantation, thus increasing the availability of organs for transplant. Furthermore, the metra® platform extends liver preservation times compared to traditional static cold storage methods.

OrganOx is also broadening its metra® technology to include kidney transplants, which are currently in development. In collaboration with eGenesis, the company has received FDA clearance to initiate a clinical study exploring the use of metra® technology combined with genetically engineered porcine livers from eGenesis for patients suffering from acute-on-chronic liver failure.

Dr. Oern R. Stuge, the Executive Chairman of OrganOx, expressed his gratitude for the investments, stating, "It is an honor and a privilege to have Intuitive Ventures and Terumo Ventures invest in OrganOx. Our board and management team look forward to working together with these industry leaders to further advance our organ technologies that save patient lives."

OrganOx was advised exclusively by Piper Sandler as the financial advisor and by Latham & Watkins in legal matters concerning this transaction.

OrganOx originated as a spin-out from the University of Oxford in 2008 and has grown into a commercial-stage organ technology company. It focuses on developing technologies that improve outcomes for patients with organ failure, whether acute or chronic. The OrganOx metra® platform has already made a significant impact by enhancing the preservation and evaluation of donor livers, thus facilitating a greater number of transplants.

Intuitive Ventures, with $250 million in assets under management, focuses on investing in companies that are pioneering advancements in minimally invasive care. Their investment strategy spans diagnostics, MedTech, therapies, and digital health. The firm emphasizes improving patient outcomes, enhancing provider experiences, and boosting the efficiency of healthcare delivery.

Terumo Ventures, established as a corporate venture capital fund, aims to foster Terumo’s growth through strategic investments. The company seeks to back innovative solutions that align with Terumo’s mission of contributing positively to society through healthcare.

The recent financial boost for OrganOx underscores the growing interest and investment in organ preservation technologies that promise to revolutionize transplantation procedures and improve patient outcomes globally.